These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 8934217

  • 1. The concentrations of the endogenous C19-steroids in hyperplastic prostatic tissue and the effect of finasteride treatment.
    Hill M, Petrik R, Hampl R, Stárka L.
    Horm Metab Res; 1996 Oct; 28(10):562-4. PubMed ID: 8934217
    [Abstract] [Full Text] [Related]

  • 2. Concentration of the endogenous antiandrogen epitestosterone and androgenic C19-steroids in hyperplastic prostatic tissue.
    Hill M, Hampl R, Petrík R, Stárka L.
    Prostate; 1996 Jun; 28(6):347-51. PubMed ID: 8650070
    [Abstract] [Full Text] [Related]

  • 3. Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by treatment with finasteride or flutamide.
    Monti S, Sciarra F, Adamo MV, Toscano V, Trotta MC, Martini C, Lanzara S, Silverio FD.
    J Androl; 1997 Jun; 18(5):488-94. PubMed ID: 9349746
    [Abstract] [Full Text] [Related]

  • 4. Finasteride for benign prostatic hyperplasia.
    Hasinski S, Miller JL, Rose LI.
    Am Fam Physician; 1992 Nov; 46(5):1511-4. PubMed ID: 1279965
    [Abstract] [Full Text] [Related]

  • 5. Finasteride treatment and neuroactive steroid formation.
    Dusková M, Hill M, Hanus M, Matousková M, Stárka L.
    Prague Med Rep; 2009 Nov; 110(3):222-30. PubMed ID: 19655698
    [Abstract] [Full Text] [Related]

  • 6. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK, Ross M, Tate R, Chisholm GD.
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
    [Abstract] [Full Text] [Related]

  • 7. Effect of long-term administration of finasteride (MK-906), an inhibitor of 5 alpha-reductase, in patients with benign prostatic hyperplasia.
    Yoshida O, Oishi K, Okada Y, Mizutani Y, Itokawa Y, Tomoyoshi T, Okada K, Komatz Y, Matsuda T, Takeuchi H.
    Hinyokika Kiyo; 1996 Apr; 42(4):323-31. PubMed ID: 8693970
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration.
    Ryu HK, Kim KM, Yoo EA, Sim WY, Chung BC.
    Br J Dermatol; 2006 Apr; 154(4):730-4. PubMed ID: 16536818
    [Abstract] [Full Text] [Related]

  • 9. [The long-term treatment of patients with benign prostatic hyperplasia using Proscar].
    Lopatkin NA, Roilans PJ, Stoner E.
    Urol Nefrol (Mosk); 1996 Apr; (1):2-4. PubMed ID: 8659035
    [Abstract] [Full Text] [Related]

  • 10. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H, Lan O, Poulain JE, Comenducci A.
    Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
    [Abstract] [Full Text] [Related]

  • 11. Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia.
    Kearney MC, Bingham J, Bergland R, Meade-D'Alisera P, Puchner PJ.
    J Urol; 2002 Jun; 167(6):2489-91. PubMed ID: 11992064
    [Abstract] [Full Text] [Related]

  • 12. [A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia].
    Pushkar' DIu, Kosko DV, Loran OB, Kan IaD, Sapozhnikov IM, Tevlin KP.
    Urol Nefrol (Mosk); 1995 Jun; (4):32-5. PubMed ID: 7571199
    [Abstract] [Full Text] [Related]

  • 13. [The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia].
    Djavan B, McConnell J.
    Wien Med Wochenschr; 1996 Jun; 146(8):165-8. PubMed ID: 8767401
    [Abstract] [Full Text] [Related]

  • 14. C19 and C21 5 beta/5 alpha metabolite ratios in subjects treated with the 5 alpha-reductase inhibitor finasteride: comparison of male pseudohermaphrodites with inherited 5 alpha-reductase deficiency.
    Imperato-McGinley J, Shackleton C, Orlic S, Stoner E.
    J Clin Endocrinol Metab; 1990 Mar; 70(3):777-82. PubMed ID: 1689740
    [Abstract] [Full Text] [Related]

  • 15. [Efficacy of finasteride in the treatment of hematuria associated with benign prostatic hypertrophy].
    Palou Redorta J, Gausa Gascon L, Salvador Bayarre J, Millán Rodríguez F, Segarra Tomás J, Villavicencio Mavrich H.
    Arch Esp Urol; 2002 Oct; 55(8):895-9. PubMed ID: 12455279
    [Abstract] [Full Text] [Related]

  • 16. 5alpha-reductase inhibitors.
    Rittmaster RS.
    J Androl; 1997 Oct; 18(6):582-7. PubMed ID: 9432130
    [No Abstract] [Full Text] [Related]

  • 17. Endocrine therapy for benign prostatic hyperplasia in the 90's.
    Ekman P.
    J Urol (Paris); 1995 Oct; 101(1):22-5. PubMed ID: 7545721
    [Abstract] [Full Text] [Related]

  • 18. [5-alpha-reductase inhibitors].
    De Jaegher K, Kozyreff P, Claes H.
    Acta Urol Belg; 1994 Dec; 62(4):23-31. PubMed ID: 7540795
    [Abstract] [Full Text] [Related]

  • 19. Finasteride in the treatment of benign prostatic hyperplasia.
    Ekman P, Andersen JT, Wolf H.
    Acta Urol Belg; 1996 Mar; 64(1):IX-XII. PubMed ID: 8659328
    [Abstract] [Full Text] [Related]

  • 20. [Hormonal therapy for benign prostatic hyperplasia].
    Sakai H, Kanetake H.
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():358-61. PubMed ID: 12599600
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.